Free shipping on all orders over $ 500

Bemcentinib

Cat. No. M2023

All AbMole products are for research use only, cannot be used for human consumption.

Bemcentinib Structure
Synonym:

R428; BGB324

Size Price Availability Quantity
5mg USD 100  USD100 In stock
10mg USD 175  USD175 In stock
50mg USD 350  USD350 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

R428 blocks the catalytic and procancerous activities of Axl. R428 inhibits Axl with low nanomolar activity and blocked Axl-dependent events, including Akt phosphorylation, breast cancer cell invasion, and proinflammatory cytokine production. R428 inhibited angiogenesis in corneal micropocket and tumor models. In vitro, R428 caused a concentration-dependent inhibition of preadipocyte differentiation into mature adipocytes, as evidenced by reduced lipid uptake. In vivo, oral administration of R428 for 5 weeks to mice kept on a high-fat diet resulted in significantly reduced weight gain and subcutaneous and gonadal fat mass. Additionally, R428 synergized with cisplatin to enhance suppression of liver micrometastasis.

Product Citations
Customer Product Validations & Biological Datas
Source Cancer Biology& Therapy (2015) . Figure 6.R428 (Abmole Bioscience, Houston, TX)
Method Western blot and MTT assay
Cell Lines MDA-MB-231 cells and MDA-MB-231 cells that were transfected with CTL or ARF1 siRNA
Concentrations 1 µ M
Incubation Time western blot (1 h) and MTT assay (24 h)
Results Interestingly, like in the EGFR inhibitor treatment, the AXL inhibitor, R428, was effective to enhance ARF1 activity. But, more importantly, this inhibitor blocked gefitinib-induced ARF1 activation. Finally, this observation was also found in MDA-MB-157 cells. However, in cells co-treated with the AXL inhibitor, R428, and gefitinib, the depletion of ARF1 was shown to have no effect further suggesting that ARF1 is signaling downstream of AXL in gefitinib treated cells (Figure 6F).
Protocol (for reference only)
Cell Experiment
Cell lines MDA-MB-231 or 4T1 cells
Preparation method Invasion Assays: MDA-MB-231 or 4T1 cells (1 × 105) were allowed to migrate through Matrigel (Millipore) toward 20% FCS in an 8-μm pore 24-well Transwell plate (BD Bio‐sciences) at 37°C for 16 to 24 h. Noninvaded cells and Matrigel were removed by swabbing. Invaded cells were fixed in 4% formaldehyde, stained with 1% crystal violet, and quantified as for Axl cellbased assay. Cells were preincubated with R428 for 3 h. R428 was added to both upper and lower Transwell chambers.
Concentrations 0, 0.03, 0.3, 3 µ M
Incubation time 3 h
Animal Experiment
Animal models Female BALB/c mice 4T1 Orthotopic Model
Formulation R428 was formulated for in vivo studies in 0.5% hydroxypropylmethylcellulose + 0.1% Tween 80.
Dosages 7–75 mg/kg twice daily
Administration oral gavage
Chemical Information
Molecular Weight 506.64
Formula C30H34N8
CAS Number 1037624-75-1
Solubility (25°C) DMSO 60 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Lijnen HR, et al. J Pharmacol Exp Ther. Growth arrest-specific protein 6 receptor antagonism impairs adipocyte differentiation and adipose tissue development in mice.

[2] Ghosh AK, et al. Blood. The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy.

[3] Holland SJ, et al. Cancer Res. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.

Related TAM Receptor Products
Axl/Mer/CSF1R-IN-2

Axl/Mer/CSF1R-IN-2 is a Axl, Mer and CSF1R inhibitor.

AXL-IN-15

AXL-IN-15 is a potent Axl inhibitor with both Ki and IC50 <1 nM.

Glesatinib

Glesatinib (MGCD265) is an orally active, potent MET/SMO dual inhibitor. Glesatinib, a tyrosine kinase inhibitor, antagonizes P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC).

DS-1205b free base 

DS-1205b free base is a potent and selective inhibitor of AXL kinase, with an IC50 of 1.3 nM. DS-1205b free base also inhibits MER, MET, and TRKA, with IC50s of 63, 104, and 407 nM, respectively. DS-1205b free base can inhibit cell migration in vitro and tumor growth in vivo.

Ningetinib Tosylate

Ningetinib Tosylate is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC50s of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2 and Axl, respectively.

  Catalog
Abmole Inhibitor Catalog




Keywords: Bemcentinib, R428; BGB324 supplier, TAM Receptor, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.